首页|Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition:Harnessing the power of nanotheranostics

Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition:Harnessing the power of nanotheranostics

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Autophagy and mitophagy pose unresolved challenges in understanding the pathology of diabetic heart condition(DHC),which encompasses a complex range of cardiovascular issues linked to diabetes and associated cardiomyopathies.Despite significant progress in reducing mortality rates from cardiovascular diseases(CVDs),heart failure remains a major cause of increased morbidity among diabetic patients.These cellular processes are essential for maintaining cellular balance and removing damaged or dysfunctional components,and their involvement in the development of diabetic heart disease makes them attractive targets for diagnosis and treatment.While a variety of conventional diagnostic and therapeutic strategies are available,DHC continues to present a significant challenge.Point-of-care diagnostics,supported by nanobiosensing techniques,offer a promising alternative for these complex scenarios.Although conventional medications have been widely used in DHC patients,they raise several concerns regarding various physiological aspects.Modern medicine places great emphasis on the application of nanotechnology to target autophagy and mitophagy in DHC,offering a promising approach to deliver drugs beyond the limitations of traditional therapies.This article aims to explore the potential connections between autophagy,mitophagy and DHC,while also discussing the promise of nanotechnology-based theranostic interventions that specifically target these molecular pathways.

AutophagyDiabetesDiabetic heart conditionMitophagyNanotheranosticsNanomedicine

Sagnik Nag、Oishi Mitra、Bhanu Maturi、Simran Preet Kaur、Ankita Saini、Muskan Nama、Soumik Roy、Souvik Samanta、Leena Chacko、Rohan Dutta、Suresh Babu Sayana、Vetriselvan Subramaniyan、Jasvinder Singh Bhatti、Ramesh Kandimalla

展开 >

Jeffrey Cheah School of Medicine and Health Sciences,Monash University Malaysia,Jalan Lagoon Selatan,47500 Bandar Sunway,Selangor,Malaysia

Department of Bio-Sciences,School of Bio-Sciences & Technology(SBST),Vellore Institute of Technology(VIT),Tiruvalam Road,Vellore 632014,Tamil Nadu,India

Department of Internal Medicine,University of Alabama at Birmingham,Birmingham,AL,USA

Department of Microbiology,University of Delhi(South Campus),Benito Juarez Road,New Delhi 110021,India

Department of Biotechnology,Indian Institute of Technology,Hyderabad(IIT-H),Sangareddy,Telangana 502284,India

BioAnalytical Lab,Meso Scale Discovery,1601 Research Blvd,Rockville,MD,USA

Department of Pharmacology,Government Medical College,Suryapet,Telangana,India

Laboratory of Translational Medicine and Nanotherapeutics,Department of Human Genetics and Molecular Medicine,School of Health Sciences,Central University of Punjab,Bathinda,India

Department of Biochemistry,Kakatiya Medical College,Warangal 506007,India

展开 >

2024

10.1016/j.ajps.2024.100927

亚洲药物制剂科学(英文版)
沈阳药科大学

亚洲药物制剂科学(英文版)

ISSN：1818-0876
年,卷(期)：2024.19(3)
  • 1